A Contemporary Approach to Hypertensive Cardiomyopathy: Reversing Left Ventricular Hypertrophy

Maximillian T. Bourdillon, Ramachandran S. Vasan

Producción científica: Review articlerevisión exhaustiva

13 Citas (Scopus)


Purpose of Review: To highlight pharmacological and non-pharmacological approaches to reversing hypertensive left ventricular hypertrophy (LVH). We identify high-risk phenotypes that may benefit from aggressive blood pressure (BP) management to prevent incident outcomes such as the development of atherosclerotic cardiovascular disease, stroke, and heart failure. Recent Findings: LVH is a modifiable risk factor. Intensive BP lowering (systolic BP < 120 mmHg) induces greater regression of electrocardiographic LVH than standard BP targets. The optimal agents for inducing LVH regression include renin–angiotensinogen-aldosterone system inhibitors and calcium channel blockers, although recent meta-analyses have demonstrated superior efficacy of non-hydrochlorothiazide diuretics. Novel agents (such as sacubitril/valsartan) and non-pharmacological approaches (like bariatric surgery) hold promise but longitudinal studies assessing their impact on clinical outcomes are needed. Summary: LVH regression is achievable with appropriate therapy with first-line antihypertensive agents. Additional studies are warranted to assess if intensive BP lowering in high-risk groups (such as blacks, women, and malignant LVH) improves outcomes.

Idioma originalEnglish (US)
Número de artículo85
PublicaciónCurrent Hypertension Reports
EstadoPublished - oct 1 2020
Publicado de forma externa

ASJC Scopus subject areas

  • Internal Medicine


Profundice en los temas de investigación de 'A Contemporary Approach to Hypertensive Cardiomyopathy: Reversing Left Ventricular Hypertrophy'. En conjunto forman una huella única.

Citar esto